Sadly — That’s… Lights Out: Chapter 11 (Again!) — For Humanigen.

I am truly sad to report, as a pure epilogue… that Humanigen has filed a chapter today. It has endured much. At one point about three years ago, it was being touted as a potential for a COVID-19 therapeutic, only to miss in the main study of that potential candidate. But it did persist, and survive — despite the Shkreli frauds in 2017… to today.

But I think this is the end of the line, for Dr. Cameron Durant’s leadership — he did a great job, but the chemistry just didn’t pan out. In truth, there is not much to move forward with. And — it seems to have caused a benign swarm, from Chinese IP addresses, all over my various life sciences review blogs. Hmmm. Here’s that bit:

Well, this is new, for 2024. [Though in truth, for most of the first half of 2013, I saw similar unexplained / inexplicable traffic, from both China and Central European IPs. I later figured that one out, to be honest. I was missing something obvious, until after July 10 2013, that year.]

This time, I haven’t a clue. And to be clear, other than Humanigen (a company we covered here, from time to time) having finally thrown in the towel, and filed a chapter… I cannot imagine that any recent life science happening would interest state actors in the PRC. Here’s that bit:

…Humanigen, once a favorite among Wall Street investors due to its prospects against COVID-19, filed for Chapter 11 bankruptcy in Wilmington, Delaware, Bloomberg Law reported Thursday, citing court papers.

The company listed $521K worth of assets and over $44M in debt in its Chapter 11 petition filed in the U.S. Bankruptcy Court for the District of Delaware….

I suppose this might be of interest to Chinese state actors (for its COVID-19 treatment candidate implications), but… more likely than not, it is just an indexing of all med- and life sciences happenings in the US that leads to the Chinese swarming. Ah well — onward, grinning.

नमस्ते